Movogesic oil 50ml


Diclofenac Diethylamine   –   2% w/v
Methyl Salicylate   –   10% w/v
Peppermint Oil   –   10% w/v
Turpentine Oil   –   10% w/v
Eucalyptus Oil   –   5% w/v
Benzyl Alcohol   –   1% v/v


50 ml

Product Description

Movogesic oil contains Diclofenac diethyl, methyl salicylate, peppermint oil, turpentine oil, eucalyptus oil and benzyl alcohol.

Diclofenac diethyl
It is NSAID and applied to skin to reduce the inflammation and to reduce pain.
Methyl salicylate
It is organic ester extracted from plant species mainly wintergreens. It is also used synthetically as fragrance in foods and beverages. When they applied to the skin it causes sudden cooling and warm feeling.
Oils in the preparation
Peppermint oil has anti-inflammatory properties causing calming and numbing effect. It may provide relief from stress, depression and mental exhaustion.

  • Musculoskeletal complaints
  • Arthritis
  • Rheumatoid arthritis
  • Polymyositis
  • Dermatomyositis
  • Osteoarthritis
  • Spondylarthritis or Ankylosing spondylitis
  • Gout attacks
  • Acute migraines
  • Post operative and post traumatic pain
  • Inflammation
  • Actinic keratosis
  • Pains associated with minor strains, sprains and contusions
Mechanism of action

Diclofenac diethyl
It causes the inhibition of prostaglandin synthesis by causing the inhibition of COX. It also possesses bacteriostatic activity by inhibition of bacterial DNA synthesis.
Methyl salicylate
It is NSAIDs with analgesic properties. The action is caused by inhibition of PG synthesis. The primary metabolite of methyl salicylate is salicylate which inhibits the synthesis of PG by irreversibly acetylating and inactivating COX.


Diclofenac diethyl
After dermal application it is well absorbed by the body about 100%. The drug follows first pass metabolism so 50% of the drug is systematically available. The mean absolute bioavailability is 55% and Tmax is 2.3 hr.
The Vd is about 1.4l/kg. About 99% of the drug is bound to protein. The diclofenac converts to its metabolites like 4′-hydroxy-, 5-hydroxy-, 3′-hydroxy-, 4′,5-dihydroxy- and 3’hydroxy-4′-methoxy-diclofenac.
The drug is excreted through urinary and biliary secretion.
The dermal bioavailability is 11.8%-30.7%. The presence of methyl- salicylate causes more penetration into the skin.
It is distributed throughout the body tissues. Salicylate is transported by low capacity saturated system out of the CSF. It follows hepatic metabolism which form conjugation with glycine to form salicyluric acid.
It is excreted in free form in urine as salicylate acid (10%) salicyluric acid (75%), salicylic phenolic (10%) and acyl (5%) glucuronides, and gentisic acid (less than 1%). Excretion depends on the pH of the urine.

  • Hypersensitivity against diclofenac
  • Associated allergic reactions
  • Third trimester of pregnancy
  • Patients with GI bleeding
  • Patients with pre-existing hepatic porphyria
  • Fluid retention and heart failure
  • Pre-existing hypertension
  • Not to be substituted for corticosteroids insufficiency
  • Abrupt discontinuation may lead to disease insufficiency
  • Anemia
  • Pre-existing asthma